Stephanie Robertson
Overview
Explore the profile of Stephanie Robertson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
727
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chen X, Sifakis E, Robertson S, Neo S, Jun S, Tong L, et al.
Proc Natl Acad Sci U S A
. 2022 Dec;
120(1):e2209856120.
PMID: 36574653
Breast cancer (BC) is a complex disease comprising multiple distinct subtypes with different genetic features and pathological characteristics. Although a large number of antineoplastic compounds have been approved for clinical...
12.
Acs B, Leung S, Kidwell K, Arun I, Augulis R, Badve S, et al.
Mod Pathol
. 2022 Jun;
35(10):1362-1369.
PMID: 35729220
Ki67 has potential clinical importance in breast cancer but has yet to see broad acceptance due to inter-laboratory variability. Here we tested an open source and calibrated automated digital image...
13.
Boyaci C, Sun W, Robertson S, Acs B, Hartman J
Biomolecules
. 2021 Nov;
11(11).
PMID: 34827609
Ki67 is an important biomarker with prognostic and potential predictive value in breast cancer. However, the lack of standardization hinders its clinical applicability. In this study, we aimed to investigate...
14.
Tanaka N, Kanatani S, Kaczynska D, Fukumoto K, Louhivuori L, Mizutani T, et al.
Nat Biomed Eng
. 2020 Jul;
4(9):875-888.
PMID: 32601394
Microscopy analysis of tumour samples is commonly performed on fixed, thinly sectioned and protein-labelled tissues. However, these examinations do not reveal the intricate three-dimensional structures of tumours, nor enable the...
15.
Robertson S, Acs B, Lippert M, Hartman J
Breast Cancer Res Treat
. 2020 Jun;
183(1):161-175.
PMID: 32572716
Purpose: The proliferation-associated biomarker Ki67 has potential utility in breast cancer, including aiding decisions based on prognosis, but has unacceptable inter- and intralaboratory variability. The aim of this study was...
16.
Robertson S, Ronnlund C, de Boniface J, Hartman J
Breast Cancer Res Treat
. 2019 Jan;
174(3):795-805.
PMID: 30659433
Purpose: The accuracy of predictive and prognostic biomarker assessment in breast cancer is paramount since these guide therapy decisions. The aim was to investigate the concordance of biomarkers and immunohistochemical...
17.
Robertson S, Stalhammar G, Darai-Ramqvist E, Rantalainen M, Tobin N, Bergh J, et al.
J Clin Pathol
. 2018 Mar;
71(9):787-794.
PMID: 29588372
Aims: The accuracy of biomarker assessment in breast pathology is vital for therapy decisions. The therapy predictive and prognostic biomarkers oestrogen receptor (ER), progesterone receptor, HER2 and Ki67 may act...
18.
Stalhammar G, Robertson S, Wedlund L, Lippert M, Rantalainen M, Bergh J, et al.
Histopathology
. 2017 Dec;
72(6):974-989.
PMID: 29220095
Aims: During pathological examination of breast tumours, proliferative activity is routinely evaluated by a count of mitoses. Adding immunohistochemical stains of Ki67 provides extra prognostic and predictive information. However, the...
19.
Robertson S, Azizpour H, Smith K, Hartman J
Transl Res
. 2017 Nov;
194:19-35.
PMID: 29175265
Breast cancer is the most common malignant disease in women worldwide. In recent decades, earlier diagnosis and better adjuvant therapy have substantially improved patient outcome. Diagnosis by histopathology has proven...
20.
Robertson S, Adolfsson J, Stattin P, Sjovall A, Winnersjo R, Hanning M, et al.
Scand J Public Health
. 2017 Apr;
45(3):230-237.
PMID: 28443490
Aims: The reported long waiting times for cancer patients have mostly been related to prognostic outcome and less to patient-related experience to outcome. We assessed waiting times for patients with...